{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erythropoiesis-stimulating+agents", "query": { "intervention": "Erythropoiesis-stimulating agents" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 55, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erythropoiesis-stimulating+agents&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T19:47:03.825Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02075463", "title": "Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Anaemia" ], "interventions": [ { "name": "GSK1278863", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2014-06-11", "completion_date": "2016-03-16", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 10, "location_summary": "Azusa, California • Glendale, California • Los Angeles, California + 7 more", "locations": [ { "city": "Azusa", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Simi Valley", "state": "California" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02075463" }, { "nct_id": "NCT03140722", "title": "Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Dialysis-Dependent Chronic Kidney Disease" ], "interventions": [ { "name": "vadadustat", "type": "DRUG" }, { "name": "epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-05-02", "completion_date": "2018-03-21", "has_results": true, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 18, "location_summary": "Bakersfield, California • Elk Grove, California • Encino, California + 15 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Elk Grove", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Lynwood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03140722" }, { "nct_id": "NCT03799627", "title": "Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Dialysis-dependent Chronic Kidney Disease" ], "interventions": [ { "name": "Vadadustat", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "DRUG" }, { "name": "Vadadustat TIW", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 175, "start_date": "2019-01-31", "completion_date": "2020-07-15", "has_results": true, "last_update_posted_date": "2022-09-29", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 41, "location_summary": "Fresno, California • Granada Hills, California • Los Angeles, California + 32 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Granada Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03799627" }, { "nct_id": "NCT01977573", "title": "A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "GSK1278863", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 252, "start_date": "2013-10-31", "completion_date": "2015-06-15", "has_results": true, "last_update_posted_date": "2018-10-12", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 25, "location_summary": "Peoria, Arizona • Azusa, California • La Mesa, California + 21 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Azusa", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01977573" }, { "nct_id": "NCT02879305", "title": "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia", "Aspergillosis, Allergic Bronchopulmonary" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2964, "start_date": "2016-09-28", "completion_date": "2020-11-09", "has_results": true, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 126, "location_summary": "Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879305" }, { "nct_id": "NCT05949684", "title": "ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Luspatercept", "type": "BIOLOGICAL" }, { "name": "Epoetin Alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 402, "start_date": "2023-10-24", "completion_date": "2031-05-30", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 33, "location_summary": "Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05949684" }, { "nct_id": "NCT05936021", "title": "Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dialysis" ], "interventions": [ { "name": "Algorithm model-based Aranesp doses", "type": "PROCEDURE" }, { "name": "Standard of care", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Intermountain Health Care, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2023-07-01", "completion_date": "2025-01-01", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 2, "location_summary": "Murray, Utah", "locations": [ { "city": "Murray", "state": "Utah" }, { "city": "Murray", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05936021" }, { "nct_id": "NCT00228449", "title": "Peginesatide for Anemia in Chronic Hemodialysis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Chronic Kidney Disease", "Chronic Renal Failure" ], "interventions": [ { "name": "peginesatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affymax", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2005-07", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2012-12-21", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Lauderdale Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00228449" }, { "nct_id": "NCT02907359", "title": "Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes", "Leukemia, Myelomonocytic, Chronic" ], "interventions": [ { "name": "Guadecitabine", "type": "DRUG" }, { "name": "Treatment Choice", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Astex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 417, "start_date": "2017-01-13", "completion_date": "2020-11-30", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 22, "location_summary": "Duarte, California • Rancho Mirage, California • Fleming Island, Florida + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Fleming Island", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02907359" }, { "nct_id": "NCT03011034", "title": "Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Talacotuzumab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2017-02-14", "completion_date": "2021-10-05", "has_results": true, "last_update_posted_date": "2025-03-04", "last_synced_at": "2026-09-23T19:47:03.825Z", "location_count": 3, "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03011034" } ] }